慢性心力衰竭经导管心脏结构性治疗的进展

金沁纯; 张蕾; 周达新

doi:10.13201/j.issn.1001-1439.2017.09.023

慢性心力衰竭经导管心脏结构性治疗的进展

- 复旦大学附属中山医院心内科(上海, 200032)

详细信息

通讯作者: 周达新, E-mail:zhou_daxin@sina.com

中图分类号: R541.6

收稿日期: 2017-01-03

Progress in transcatheter structual cardiac therapies for chronic heart failure

- Department of Carrdiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

More Information

Corresponding author: ZHOU Daxin, E-mail: zhou_daxin@sina.com

Received Date: 03 January 2017

摘要

摘要: 慢性心力衰竭是多数心血管疾病的最终归宿,在心脏泵血、充盈能力的下降的同时,往往伴有心肌重构。在过去的2个世纪,随着药物治疗的不断发展,再同步化治疗、植入式心律转复除颤器等新技术的不断普及,心力衰竭患者的预后得到了改善,但慢性心力衰竭的发病率和病死率仍然居高不下。近年来,随着介入治疗和器械的不断发展,各种经导管心脏结构性治疗的方法不断涌现,给慢性心力衰竭患者的治疗带来了新希望。本文针对上述经导管结构性治疗慢性心力衰竭的技术作一介绍。
- 慢性心力衰竭 /
- 结构性治疗 /
- 经导管
Abstract: Chronic heart failure (CHF) is the end stage of various kinds of cardiovascular diseases.The significant disability of the cardiac contract-stretch function is always accompanied by myocardial remodeling.In the past two decades, improvements in drug therapy, together with wide-spread application of cardiac resynchronization therapy devices and implantable cardioverter defibrillators have ameliorated the prognosis of CHF patients, however the morbidity and mortality of CHF remain high.Nowadays, with the rapid development of interventional methods and instruments, several catheter-based structural heart therapies have emerged and tend to be promising for CHF patients.In this review, these technologies of transcatheter structual treatments are summarized.
- chronic heart failure /
- structual heart therapies /
- transacatheter

HTML全文

参考文献(45)

[1]	刘娜, 邢波.经皮心室重建术最新研究进展[J].心血管病学进展, 2014, 35 (5):555-558.
[2]	邢作英, 王永霞, 朱明军.慢性心力衰竭流行病学研究现状及其病因[J].中华实用诊断与治疗杂志, 2012, 26 (10):937-938.
[3]	杨跃进, 胡奉环, 宋雷.左心衰竭介入治疗的热点——经导管心室隔离成形术[J].中国循环杂志, 2015, 30 (6):513-515.
[4]	汤学超, 秦永文.经皮心室重建术——心力衰竭治疗新手段[J].介入放射学杂志, 2016, 25 (5):453-455.
[5]	COSTA M A, MAZZAFERRI E L JR, SIEVERT H, et al.Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure:three-year outcomes of the PARACHUTE firstin-human study[J].Circ Heart Fail, 2014, 7:752-758.
[6]	MAZZAFERRI E L JR, GRADINAC S, SAGIC D, et al.Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction:Results of the PercutAneous Ventricular RestorAtion in Chronic Heart failUre PaTiEnts Trial[J].Am Heart J, 2012, 163:812-820.
[7]	THOMAS M, NIENABER C A, INCE H, et al.Percutaneous ventricular restoration (PVR) therapy using the Parachute device in 100subjects with ischaemic dilated heart failure:one-year primary endpoint results of PARACHUTEⅢ, a European trial[J].EuroIntervention, 2015, 11:710-717.
[8]	LADICH E, OTSUKA F, VIRMANI R.A pathologic study of explanted parachute devices from seven heart failure patients following percutaneous ventricular restoration[J].Catheter Cardiovasc Interv, 2014, 83:619-630.
[9]	TOTH G G, VANDERHEYDEN M, BARTUNEK J.Novel device-based interventional strategies for advanced heart failure[J].Postepy Kardiol Interwencyjnej, 2016, 12:13-16.
[10]	SФNDERGAARD L, REDDY V, KAYE D, et al.Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure[J].Eur J Heart Fail, 2014, 16:796-801.
[11]	AMAT-SANTOS I J, BERGERON S, BERNIER M, et al.Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure:first-in-man experience with the V-Wave device[J].EuroIntervention, 2015, 10:1127-1131.
[12]	HASENFUSS G, HAYWARD C, BURKHOFF D, et al.A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCELAP-HF):a multicentre, open-label, single-arm, phase 1trial[J].Lancet, 2016, 387:1298-1304.
[13]	刘晓莉, 肖培林.经导管消融选择性去肾交感神经治疗——未来心力衰竭治疗的热点[J].心血管病学进展, 2013, 34 (3):378-381.
[14]	王真, 张瑞岩.经导管去肾交感神经术治疗慢性心力衰竭[J].国际心血管病杂志, 2014:(4):239-242.
[15]	SCHIRMER S H, SAYED M M Y A, REIL J, et al.Improvements in Left Ventricular Hypertrophy and Diastolic Function Following Renal Denervation[J].JAm Coll Cardiol, 2014, 63:1916-1923.
[16]	BRANDT M C, MAHFOUD F, REDA S, et al.Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension[J].J Am Coll Cardiol, 2012, 59:901-909.
[17]	DAVIES J E, MANISTY C H, PETRACO R, et al.First-in-man safety evaluation of renal denervation for chronic systolic heart failure:Primary outcome from REACH-Pilot study[J].Int J Cardiol, 2013, 162:189-192.
[18]	施雯.慢性心力衰竭远程监测的临床应用[J].心血管病学进展, 2011, 32 (5):653-656.
[19]	ABRAHAM W T, ADAMSON P B, HASAN A, et al.Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failure[J].Am Heart J, 2011, 161:558-566.
[20]	RITZEMA J, MELTON I C, RICHARDS A M, et al.Direct Left Atrial Pressure Monitoring in Ambulatory Heart Failure Patients:Initial Experience With a New Permanent Implantable Device[J].Circulation, 2007, 116:2952-2959.
[21]	RITZEMA J, TROUGHTON R, MELTON I, et al.Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure[J].Circulation, 2010, 121:1086-1095.
[22]	RAINA A, KANWAR M.New Drugs and Devices in the Pipeline for Heart Failure with Reduced Ejection Fraction Versus Heart Failure with Preserved Ejection Fraction[J].Current Heart Failure Reports, 2014, 11:374-381.
[23]	TRICHON B H, FELKER G M, SHAW L K, et al.Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure[J].The American Journal of Cardiology, 2003, 91:538-543.
[24]	徐宝华, 李楠, 马林.功能性二尖瓣反流程度与慢性心力衰竭预后相关性研究[J].当代医学, 2013, 19 (34):52-53.
[25]	周达新, 葛均波.经皮二尖瓣反流的介入治疗[J].心血管病学进展, 2013, 34 (5):608-609.
[26]	潘文志, 周达新, 葛均波.经导管缘对缘二尖瓣修复术的研究进展[J].中国医学前沿杂志 (电子版), 2012, 4 (8):14-18.
[27]	ST GOAR F G, FANN J I, KOMTEBEDDE J, et al.Endovascular edge-to-edge mitral valve repair:shortterm results in a porcine model[J].Circulation, 2003, 108:1990-1993.
[28]	PERLOWSKI A, ST GOAR F, GLOWER D G, et al.Percutanenous therapies for mitral regurgitation[J].Curr Probl Cardiol, 2012, 37:42-68.
[29]	潘文志, 钱菊英.经皮二尖瓣修复术的现状和展望[J].中国心血管杂志, 2013, 18 (6):416-419.
[30]	葛均波.评国内首例经导管二尖瓣修复术成功[J].中国介入心脏病学杂志, 2012, 20 (3):121-122.
[31]	MAURI L, FOSTER E, GLOWER D D, et al.4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation[J].JAm Coll Cardiol, 2013, 62:317-328.
[32]	FELDMAN T, FOSTER E, GLOWER D D, et al.Percutaneous repair or surgery for mitral regurgitation[J].N Engl J Med, 2011, 364:1395-1406.
[33]	WHITLOW P L, FELDMAN T, PEDERSEN W R, et al.Acute and 12-month results with catheter-based mitral valve leaflet repair:the EVERESTⅡ (Endovascular Valve Edge-to-Edge Repair) High Risk Study[J].J Am Coll Cardiol, 2012, 59:130-139.
[34]	FELDMAN T, KAR S, RINALDI M, et al.Percutaneous mitral repair with the MitraClip system:safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort[J].J Am Coll Cardiol, 2009, 54:686-694.
[35]	SMITH T, MCGINTY P, BOMMER W, et al.Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system[J].Catheter Cardiovasc Interv, 2012, 80:678-685.
[36]	SEEBURGER J, RINALDI M, NIELSEN S L, et al.Off-pump transapical implantation of artificial neochordae to correct mitral regurgitation:the TACT Trial (Transapical Artificial Chordae Tendinae) proof of concept[J].J Am Coll Cardiol, 2014, 63:914-919.
[37]	MACHAALANY J, BILODEAU L, HOFFMANN R, et al.Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system:results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial[J].Am Heart J, 2013, 165:761-769.
[38]	HARNEK J, WEBB J G, KUCK K H, et al.Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation:1-year results from the EVOLUTION phase I study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation)[J].JACC Cardiovasc Interv, 2011, 4:115-122.
[39]	SCHOFER J, SIMINIAK T, HAUDE M, et al.Percutaneous Mitral Annuloplasty for Functional Mitral Regurgitation:Results of the CARILLON Mitral Annuloplasty Device European Union Study[J].Circulation, 2009, 120:326-333.
[40]	LIPIECKI J, SIMINIAK T, SIEVERT H, et al.Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation:the TITANⅡtrial[J].Open Heart, 2016, 3:e411.
[41]	GOEL R, WITZEL T, DICKENS D, et al.The QuantumCor device for treating mitral regurgitation:an animal study[J].Catheter Cardiovasc Interv, 2009, 74:43-48.
[42]	JILAIHAWI H, VIRMANI R, NAKAGAWA H, et al.Mitral annular reduction with subablative therapeutic ultrasound:pre-clinical evaluation of the ReCor device[J].EuroIntervention, 2010, 6:54-62.
[43]	NICKENIG G, SCHUELER R, DAGER A, et al.Treatment of Chronic Functional Mitral Valve Regurgitation With a Percutaneous Annuloplasty System[J].J Am Coll Cardiol, 2016, 67:2927-2936.
[44]	SIMINIAK T, DANKOWSKI R, BASZKO A, et al Przezskórna bezposrednia annuloplastyka mitralna za pomocą systemu Mitralign Bident ^TM:prezentacja metody i opis przypadku[J].Kardiologia Polska, 2013, 71:1287-1292.
[45]	BAPAT V, BUELLESFELD L, PETERSON M D, et al.Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device[J].EuroIntervention, 2014, 10Suppl U:U120-U128.